Revvity, Inc.
NYSE:RVTYMedical - Diagnostics & Research
Healthcare
$152.43 -3.36%
-$3.40 today
- Market cap
- $17.02B
- Beta
- 1.11
- P/E (TTM)
- 45.4
- EPS (TTM)
- $2.15
- Dividend yield
- 0.29%
52W Low $81.22High $118.30
Volume 1.09M
Average 1.27M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
$581.78M
FY 2025 · Annual
-7.4% YoYInvesting Cash Flow
-$17.35M
FY 2025 · Annual
Financing Cash Flow
-$855.05M
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 889.44M | 512.68M | 179.5M | 283.07M | 241.2M |
| Depreciation & Amortization | 311.44M | 427M | 431.77M | 427.85M | 405.34M |
| Deferred Income Tax | (53.4M) | (107.41M) | (97.48M) | (110.31M) | (61.48M) |
| Stock-Based Compensation | 29.68M | 51.52M | 41.41M | 37.81M | 22.85M |
| Change in Working Capital | 132.99M | (262.97M) | (391.35M) | (18.31M) | (96.78M) |
| Accounts Receivables | 165.59M | 66.09M | (9M) | (15.97M) | (101.02M) |
| Inventory | 32.28M | (48.63M) | (14.11M) | 45.09M | 14.78M |
| Accounts Payables | (7.58M) | (43.8M) | (76.43M) | (26.03M) | 7.35M |
| Other Working Capital | (57.3M) | (236.62M) | (291.81M) | (21.4M) | (17.89M) |
| Other Non-Cash Items | 100.61M | 59M | (72.58M) | 8.18M | 70.65M |
| Operating Cash Flow | 1.41B | 679.81M | 91.27M | 628.3M | 581.78M |
| Capital Expenditures | (86.02M) | (85.63M) | (81.37M) | (86.65M) | (73.52M) |
| Acquisitions (Net) | (3.98B) | 6.99M | (1.93M) | 0 | 0 |
| Purchases of Investments | (23.13M) | (47.18M) | (1.23B) | (6.59M) | (385K) |
| Sales of Investments | 0 | 8.89M | 550M | 712.5M | 0 |
| Other Investing Activities | (22.96M) | (15.92M) | 2.07B | 156.9M | 56.55M |
| Investing Cash Flow | (4.11B) | (132.85M) | 1.31B | 776.16M | (17.35M) |
| Debt Repayment | 3.04B | (559.17M) | (517.49M) | (723.07M) | (521K) |
| Common Stock Issued | 25.12M | 14.11M | 0 | 0 | 2.93M |
| Common Stock Repurchased | (73.07M) | (80.64M) | (388.88M) | (369.58M) | (820.82M) |
| Dividends Paid | (32.37M) | (35.34M) | (34.97M) | (34.45M) | (32.8M) |
| Other Financing Activities | (21M) | (767K) | (5.79M) | (1.13M) | (3.84M) |
| Financing Cash Flow | 2.94B | (661.8M) | (947.12M) | (1.13B) | (855.05M) |
| Effect of Forex Changes | (22.93M) | (33.75M) | (14.05M) | (26.15M) | 46.04M |
| Net Change in Cash | 216.72M | (148.59M) | 443.63M | 250.08M | (244.59M) |
| Free Cash Flow | 1.32B | 594.18M | 9.9M | 541.65M | 508.26M |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income$241.2M
+ D&A$405.3M
+ Stock-Based Comp$22.8M
- Deferred Tax-$61.5M
- Working Capital-$96.8M
+ Other Non-Cash$70.7M
= Operating Cash Flow$581.8M
- Capex-$73.5M
= Free Cash Flow$508.3M
Analysis
FY2025 free cash flow is $508.3M. FCF conversion is 210.7% of net income. Operating cash flow was $581.8M, with capex of -$73.5M. The largest bridge item is D&A at $405.3M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 8-K | Current report | Nov 3, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 7, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 2, 2026 |
Does RVTY generate free cash flow?
Revvity, Inc. (RVTY) generated $508.25M of free cash flow in fiscal 2025.
How much operating cash flow does RVTY produce?
Operating cash flow was $581.78M, before capital expenditures of $73.52M.
Continue the stock analysis
Jump to another research area for this company.